Literature DB >> 11253328

Normothermic versus hypothermic perfusion during cardiopulmonary bypass. A randomized study on 132 patients.

E Parodi1, A Lijoi, F Scarano, A Podestà, S Cisico, A Brisighella, G C Passerone.   

Abstract

BACKGROUND: A prospective randomized trial to compare normothermic CPB with hypothermic CPB has been performed.
METHODS: 132 patients undergoing CPB were randomized into two groups: group 1 underwent normothermic CPB and group 2 hypothermic CPB (between 26 and 30 degrees C).
RESULTS: Any significant difference was observed between the groups with regard to hospital mortality, blood transfusions, incidence of neurologic deficits and hematocrit, blood hemoglobin levels, platelet counts, plasma concentrations of glutamic-pyruvic transminase, glutamic-oxaloacetic transaminase, creatine kinase, valued at the 12th and 24th postoperative hour and at the 2nd, 3rd, and 4th postoperative day. A significant difference was observed between the groups with regard to tracheal extubation time, discharge time from the intensive care unit and inotropic drug infusion. The normothermic CPB patients group needed shorter time for tracheal extubation and discharge from the intensive care unit: this difference may be ascribed to a shorter inotropic drug infusion. Any increased surgical risks have been observed.
CONCLUSIONS: In conclusion, we think that normothermic CPB is favourable because it can reduce costs, it can improve the management of a cardiac surgery unit and it is more comfortable for patients.

Entities:  

Mesh:

Year:  2000        PMID: 11253328

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  1 in total

1.  Rewarming Rate During Cardiopulmonary Bypass Is Associated With Release of Glial Fibrillary Acidic Protein.

Authors:  Daijiro Hori; Allen D Everett; Jennifer K Lee; Masahiro Ono; Charles H Brown; Ashish S Shah; Kaushik Mandal; Joel E Price; Laeben C Lester; Charles W Hogue
Journal:  Ann Thorac Surg       Date:  2015-07-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.